The rising popularity of weight-loss drugs like Ozempic and other GLP-1 medications is creating a new financial challenge for employers. As more workers seek coverage for these treatments, companies are facing higher healthcare costs, difficult benefit decisions, and growing pressure to balance access with affordability.
This episode explores why employer health plans are struggling with the cost of weight-loss drugs, how businesses are responding, and what the debate means for workers, insurers, drugmakers, and the future of workplace healthcare benefits.
Podcast: Play in new window | Download
